These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
123 related articles for article (PubMed ID: 12169049)
1. From the Food and Drug Administration. Crawford LM JAMA; 2002 Aug; 288(6):688. PubMed ID: 12169049 [No Abstract] [Full Text] [Related]
2. FDA approves restricted marketing of Lotronex. FDA Consum; 2002; 36(4):4. PubMed ID: 12184306 [No Abstract] [Full Text] [Related]
3. Contemporary thoughts on the treatment of irritable bowel syndrome. Giaquinta D Manag Care Interface; 2002 Aug; 15(8):19-20, 22. PubMed ID: 12229060 [No Abstract] [Full Text] [Related]
4. Alosetron to return to market. Young D Am J Health Syst Pharm; 2002 Jul; 59(14):1323-4. PubMed ID: 12132555 [No Abstract] [Full Text] [Related]
5. FDA advisory panels recommend Lotronex be put back on market. Charatan F BMJ; 2002 May; 324(7345):1053. PubMed ID: 11993482 [No Abstract] [Full Text] [Related]
6. Lotronex and the FDA: a fatal erosion of integrity. Horton R Lancet; 2001 May; 357(9268):1544-5. PubMed ID: 11377636 [No Abstract] [Full Text] [Related]
7. FDA OK's two drugs for irritable bowel syndrome. The arsenal of IBS drugs is growing, but diagnosis is tricky. Horwitz BJ Health News; 2002 Oct; 8(10):1-2. PubMed ID: 12416480 [No Abstract] [Full Text] [Related]
8. National policies for xenotransplantation in the USA. Bloom ET Xenotransplantation; 2007 Jul; 14(4):345-6. PubMed ID: 17669177 [TBL] [Abstract][Full Text] [Related]
10. Irritable bowel syndrome. A poorly understood disorder. Lewis C FDA Consum; 2001; 35(4):30-6. PubMed ID: 11692885 [No Abstract] [Full Text] [Related]
11. The FDA and The Lancet: an exchange. Christensen J Lancet; 2001 Aug; 358(9279):417; author reply 417-8. PubMed ID: 11503622 [No Abstract] [Full Text] [Related]
12. The FDA and The Lancet: an exchange. Walker A Lancet; 2001 Aug; 358(9279):417; author reply 417-8. PubMed ID: 11503621 [No Abstract] [Full Text] [Related]
13. The FDA and The Lancet: an exchange. Malozowski S Lancet; 2001 Aug; 358(9279):416-7; author reply 417-8. PubMed ID: 11503620 [No Abstract] [Full Text] [Related]
14. The FDA and The Lancet: an exchange. Hirschfeld S; Kieffer L; McGuinn WD; Rothmann M; Timmer WC Lancet; 2001 Aug; 358(9279):415-6; author reply 417-8. PubMed ID: 11503618 [No Abstract] [Full Text] [Related]
15. The FDA and The Lancet: an exchange. Galson S; Kweder S; Houn F; Raczkowski V; Honig PK Lancet; 2001 Aug; 358(9279):415; author reply 417-8. PubMed ID: 11503619 [No Abstract] [Full Text] [Related]
16. FDA draws patients into alosetron risk management. Miller JL Am J Health Syst Pharm; 2000 Oct; 57(19):1736. PubMed ID: 11030021 [No Abstract] [Full Text] [Related]
17. End points in irritable bowel syndrome. Mangel AW; Fehnel SE Expert Rev Gastroenterol Hepatol; 2011 Jun; 5(3):293-5. PubMed ID: 21651345 [No Abstract] [Full Text] [Related]
18. New FDA xenotransplantation documents: a proposed rule and a draft guidance. Bloom ET Xenotransplantation; 2001 Aug; 8(3):153-4. PubMed ID: 11472622 [No Abstract] [Full Text] [Related]
19. Alosetron use drops dramatically with risk management. Traynor K Am J Health Syst Pharm; 2004 Jun; 61(12):1210-2. PubMed ID: 15259746 [No Abstract] [Full Text] [Related]
20. Report of the Food and Drug Administration Subcommittee on Xenotransplantation: meeting of 13 January 2000, Center for Biologics Evaluation and Research. Xenotransplantation Subcommittee (Subcmomittee of the Biological Response Modifiers Advisory Commitee). Fod and Drug Administration, Xenotransplantation; 2000 May; 7(2):75-9. PubMed ID: 10961289 [No Abstract] [Full Text] [Related] [Next] [New Search]